Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of bempedoic acid in high cardiovascular risk patients with hyperlipidemia
2015-004136-36Phase 3Completed
- Sponsor
- Esperion Therapeutics
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia, familial hypercholesterolemia (FH), atherosclerotic disease and 1 more comparing Bempedoic acid 180 mg with Placebo (2 arms). Primary endpoint: General safety. Started Mar 2016; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)atherosclerotic diseasehyperlipidemia
Beyond the preview
Go deeper on 2015-004136-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004136-36.